ASX RELEASE 22 November 2017 KAZIA THERAPEUTICS – CLARIFICATION...

ASX RELEASE 22 November 2017 KAZIA THERAPEUTICS – CLARIFICATION OF MEDIA REPORT Sydney, 22 November 2017 – Kazia Therapeutics Limited (ASX: NRTDA; NASDAQ: NVGN), formerly Novogen Limited (the Company), an Australian oncology drug development company, seeks to provide clarification to shareholders regarding a recent media report referring to Noxopharm Limited (ASX: NOX) and Dr Graham Kelly, who is the Managing Director and Chief Executive Officer of Noxopharm, and a former CEO of the Company. The media report stated that NOX66 (Noxopharm's lead program) was designed by Dr Graham Kelly when he was an employee of the Company. Following the publication of that report in online media on Monday 20 November 2017, the Company has become aware of speculation among certain of its shareholders regarding the Company's intellectual property position. Accordingly, the Company considers itself obliged to provide a public statement in accordance with its continuous disclosure obligations under ASX Listing Rule 3.1. The Company considers the protection of its intellectual property to be among its highest responsibilities to shareholders and in this regard is in ongoing discussions with both Dr Kelly and Noxopharm through the parties' respective lawyers. For clarity, the matters under discussion with Noxopharm have no bearing on the intellectual property associated with the Company's own development programs. ENDS